Indo US Bio-Tech Ltd.

•
₹ 85.56-0.47%

2026-08-21

indousagriseeds.comBSE: 541304NSE: INDOUS
Market Cap₹ 173 Cr.
Current Price₹ 86
High / Low₹ 159 / 75
Stock P/E34.1
Book Value—
Price to Book—
Dividend Yield0.00 %
ROCE15.5 %
ROE16.9 %
Face Value₹ 10

Add ratio to table

ABOUT

KEY POINTS

Revenue Breakup Mar 2022 • Agriculture Activities: 88.9% • Trading Activity: 11.1%

PROS

  • Company maintains a comfortable, low leverage position

CONS

  • Poor cash conversion - profits are not backed by operating cash flow (CFO/PAT 0.16x)
  • Effective tax rate is unusually low at 4.7% - earnings may be flattered
  • Working capital days have increased from 182 to 252 days
  • Free cash flow has been persistently negative
  • Though reporting repeated profits, the company pays out little dividend (0.0%)
  • Inventory has been piling up - inventory days up from 96 to 128

* The pros and cons are machine generated based on quantitative rules.

Peer comparison

EDIT COLUMNS
Fast Moving Consumer GoodsAgriAgriculture
Part ofNIFTY 50NIFTY 500NIFTY LARGEMIDCAP 250NIFTY 100NIFTY 200
S.No.NameCMP Rs.P/EMar Cap Rs.Cr.Div Yld %NP Qtr Rs.Cr.Qtr Profit Var %Sales Qtr Rs.Cr.Qtr Sales Var %ROCE %OPM %
1.KSCL768.9015.853955.150.00279.84-14.47742.50-13.5121.7739.58
2.VENKEYS1502.25308.042116.270.6749.99215.791118.3829.1711.276.18
3.AVTNPL87.1515.841327.160.9231.10156.69241.2282.1614.2616.56
4.REGAAL97.080.00999.860.26133.281369.952021.49719.8516.9115.33
5.BSHSL88.720.00931.000.0014.3016.56182.5719.3721.199.39
6.NATHBIOGEN154.007.99292.661.3032.26-13.46328.4015.766.8910.70
7.INDOUS86.2034.14172.850.003.04-35.3832.997.2121.1512.01
8.MSL145.0019.15159.210.003.971.9361.8425.8112.349.28
9.OSWALSEEDS13.309.96121.660.0012.2768.60117.0819.539.8815.65
10.NARMADA14.440.00110.770.007.54—222.63—8.944.25
11.AGRITECH101.300.0060.170.00-3.6161.180.00—-1.10—
12.ANTGRAPHIC0.730.0011.320.005.51695.09404.128005.09-1.591.46
Detailed Comparison with:

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

No quarterly results found

We don't have this information yet. Please check back later.

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2020
40
36
Operating Profit
4
OPM %
10
Other Income
0
Interest
1
Depreciation
0
3
Tax %
11
Net Profit
3
EPS
4
Dividend Payout %
0
Minority Interest
0
Share of Associates
0
Adjusted EPS
2
Minority Interest
0
Share of Associates
0
Adjusted EPS
2
Mar 2021
40
35
Operating Profit
5
OPM %
13
Other Income
0
Interest
1
Depreciation
0
4
Tax %
-25
Net Profit
5
EPS
8
Dividend Payout %
0
Minority Interest
0
Share of Associates
0
Adjusted EPS
3
Minority Interest
0
Share of Associates
0
Adjusted EPS
3
Mar 2022
50
43
Operating Profit
7
OPM %
14
Other Income
0
Interest
1
Depreciation
0
5
Tax %
5
Net Profit
5
EPS
8
Dividend Payout %
0
Minority Interest
0
Share of Associates
0
Adjusted EPS
3
Minority Interest
0
Share of Associates
0
Adjusted EPS
3

COMPOUNDED SALES GROWTH

10 Years:
—
5 Years:
—
3 Years:
—

COMPOUNDED PROFIT GROWTH

10 Years:
—
5 Years:
—
3 Years:
—

STOCK PRICE CAGR

10 Years:
—
5 Years:
—
3 Years:
—
1 Year:
-43%

RETURN ON EQUITY

10 Years:
—
5 Years:
—
3 Years:
19%
Last Year:
17%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Corporate actions

2023

Aug 29

1:1

Increase in Authorised Capital & Bonus issue & Inter alia, to consider and approve :- (1) To increase Authorised Share Capital of the Company. (2) To recommend for the Issue of Bonus Shares to the existing Shareholders of the company. (3) To Call the Extra Ordinary General Meeting for the purpose of approval of above agendas. (4) Any other Matter with the permission of the Chair.

2021

Nov 29

1:5

2019

Apr 23

1:4

Bonus issue & Increase in Authorised Capital The Company is going to discuss about following main agenda. 1. To Increase Authorized Share Capital of the Company. 2. To discuss and approve the Issue of Bonus Shares which will be Subject to approval of the Shareholders at General Meeting. 3. To take note of Resignation of Mr. Dhiren Vithaldas Savalia from the post of Independent Director of the Company.

Mar 2020
Equity Capital
6
10
7
Trade Payables
8
3
Total Liabilities
35
1
Capital Work in Progress
1
9
0
23
Total Assets
35
Total Debt
9
Net Working Capital
15
Contingent Liabilities
0
Book Value per Share
27.05
Face Value
10.00
Total Debt
9
Net Working Capital
15
Contingent Liabilities
0
Book Value per Share
27.05
Face Value
10.00
Mar 2021
Equity Capital
6
15
8
Trade Payables
9
6
Total Liabilities
43
2
Capital Work in Progress
2
12
0
27
Total Assets
43
Total Debt
12
Net Working Capital
20
Contingent Liabilities
1
Book Value per Share
35.15
Face Value
10.00
Total Debt
12
Net Working Capital
20
Contingent Liabilities
1
Book Value per Share
35.15
Face Value
10.00
Mar 2022
Equity Capital
9
29
8
Trade Payables
3
6
Total Liabilities
55
6
Capital Work in Progress
2
23
0
24
Total Assets
55
Total Debt
13
Net Working Capital
35
Contingent Liabilities
1
Book Value per Share
42.01
Face Value
10.00
Total Debt
13
Net Working Capital
35
Contingent Liabilities
1
Book Value per Share
42.01
Face Value
10.00

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2020
-1
Cash from Investing
-1
Cash from Financing
2
0
Free Cash Flow
-1
OCF / Net Profit
-0.33
Cumulative 5-Year FCF
0
OCF / Net Profit
-0.33
Cumulative 5-Year FCF
0
Mar 2021
0
Cash from Investing
-2
Cash from Financing
2
-0
Free Cash Flow
-2
OCF / Net Profit
0.03
Cumulative 5-Year FCF
0
OCF / Net Profit
0.03
Cumulative 5-Year FCF
0
Mar 2022
3
Cash from Investing
-5
Cash from Financing
3
-0
Free Cash Flow
-1
OCF / Net Profit
0.53
Cumulative 5-Year FCF
0
OCF / Net Profit
0.53
Cumulative 5-Year FCF
0

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2020
EPS (₹)
4.18
Book Value (₹)
27.05
Dividend per Share (₹)
0.00
Cash EPS (₹)
1.89
Operating Margin %
9.99%
Net Margin %
6.37%
ROE %
15.44%
ROCE %
15.00%
7.31%
Debtor Days
193
Inventory Days
84
Payable Days
667
-391
Debt to Equity (x)
0.52x
Interest Coverage (x)
4.24x
1.91x
Revenue Growth %
0.00%
Operating Profit Growth %
0.00%
Net Profit Growth %
0.00%
0.00%
P/E (x)
0.00x
P/B (x)
0.00x
Dividend Yield %
0.00%
0.00x
Mar 2021
EPS (₹)
8.07
Book Value (₹)
35.15
Dividend per Share (₹)
0.00
Cash EPS (₹)
3.54
Operating Margin %
13.38%
Net Margin %
12.22%
ROE %
25.96%
ROCE %
17.65%
12.54%
Debtor Days
208
Inventory Days
96
Payable Days
0
304
Debt to Equity (x)
0.54x
Interest Coverage (x)
4.33x
2.11x
Revenue Growth %
0.88%
Operating Profit Growth %
35.18%
Net Profit Growth %
93.30%
0.00%
P/E (x)
0.00x
P/B (x)
0.00x
Dividend Yield %
0.00%
0.00x
Mar 2022
EPS (₹)
5.52
Book Value (₹)
42.01
Dividend per Share (₹)
0.00
Cash EPS (₹)
3.01
Operating Margin %
13.90%
Net Margin %
10.11%
ROE %
16.92%
ROCE %
15.46%
10.27%
Debtor Days
165
Inventory Days
128
Payable Days
-235
529
Debt to Equity (x)
0.33x
Interest Coverage (x)
5.42x
3.81x
Revenue Growth %
24.80%
Operating Profit Growth %
29.62%
Net Profit Growth %
3.34%
0.00%
P/E (x)
0.00x
P/B (x)
0.00x
Dividend Yield %
0.00%
0.00x

Shareholding Pattern

Numbers in percentages

TRADES
Jun 2024
70.17
0.00
DIIs
0.00
Government
0.00
29.83
Sep 2024
70.17
0.00
DIIs
0.00
Government
0.00
29.83
Dec 2024
70.17
0.00
DIIs
0.00
Government
0.00
29.82
Mar 2025
70.17
0.00
DIIs
0.00
Government
0.00
29.83
Jun 2025
70.17
0.00
DIIs
0.00
Government
0.00
29.83
Sep 2025
70.17
0.00
DIIs
0.00
Government
0.00
29.83
Dec 2025
70.17
0.00
DIIs
0.00
Government
0.00
29.83
Mar 2026
68.29
0.18
DIIs
0.00
Government
0.00
31.53
Jun 2026
68.29
0.01
DIIs
0.00
Government
0.00
31.70

Documents

Announcements

  • Copy of Newspaper Publication

    2026-08-13 - Indo Us Biotech Limited has informed the Exchange about Copy of Newspaper Publication relating to unaudited quarterly Financial Results for the quarter ended on 30th June, 2026

  • Integrated Filing- Financial

    2026-08-12 - Submission of Standalone Unaudited Financial Results of the Company for the quarter ended June 30, 2026.

Annual Reports

Credit Ratings

Nothing filed yet.

Concalls

Nothing filed yet.